UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2014

o	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________________ to __________________________

Commission file number: 000-55149

AV THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		33-1222799
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

20 East 68th Street, Suite 204

New York, NY 10065

(Address of principal executive offices)

10065

(zip code)

(917) 497-5523

(Registrant's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o		Accelerated filer o
Non-accelerated filer o (Do not check if smaller reporting company)		Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

Yes o No þ

81,880,963 shares of common stock are issued and outstanding as of ~~August~~November 1514, 2014.

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

FORM 10-Q

TABLE OF CONTENTS

June 30, 2014

		Page

PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	3

	Condensed Consolidated Balance Sheets at September 30, 2014 and December 31, 2013	3

	Condensed Consolidated Statements of Operations for the Nine Months Ended September 30, 2014 and 2013	4

	Condensed Consolidated Statements of Operations for the Three Months Ended September 30, 2014 and 2013	5

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2014 and 2013	6

	Notes to Condensed Consolidated Statements	7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20

Item 4	Controls and Procedures	20

PART II - OTHER INFORMATION
		21
Item 1.	Legal Proceedings
		21
Item 1A.	Risk Factors

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21

Item 3.	Defaults Upon Senior Securities	21

Item 4.	Mine Safety Disclosures	21

Item 5.	Other Information	21

Item 6.	Exhibits	21

Signatures		22

		Page
PART I - FINANCIAL INFORMATION		3
Item 1.	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets at June 30, 2014 and December 31, 2013	3
	Condensed Consolidated Statements of Operations for the Six Months Ended June 30, 2014 and 2013	4
	Condensed Consolidated Statements of Operations for the Three Months Ended June 30, 2014 and 2013	5
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2014 and 2013	6
	Notes to Condensed Consolidated Statements	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	18
Item 4	Controls and Procedures	18
PART II - OTHER INFORMATION		20
Item 1.	Legal Proceedings	20
Item 1A.	Risk Factors	20
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3.	Defaults Upon Senior Securities	20
Item 4.	Mine Safety Disclosures	20
Item 5.	Other Information	20
Item 6.	Exhibits	20
Signatures		21

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

AV Therapeutics, Inc. and Subsidiary

CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS
	June 30, 2014			December 31, 2013
	September 30, 2014			December 31, 2013
	(Unaudited)
Current assets:
Cash	$	~~471~~273,~~084~~222		$	576,251
Prepaid expenses		3020,750			60,000
Total current assets		~~501~~293,~~834~~972			636,251
Property and equipment, net of accumulated depreciation of $1,295 and $1,079, respectively		863			1,079
Property and equipment, net of accumulated depreciation of $1,403 and $1,079, respectively		755			1,079
Intangible assets, net of accumulated amortization of $92,491 and $82,403, respectively		137,509			147,597
Intangible assets, net of accumulated amortization of $97,535 and $82,403, respectively		132,465			147,597
Total assets	$	~~640~~427,~~206~~192		$	784,927
LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	~~529~~465,~~103~~193		$	452,050
Derivative liability - warrants		~~419~~192,~~026~~122			-
Notes payable		97,000			97,000
Notes payable - related parties		197,705			201,705
Total current liabilities		1952,~~242,834~~020			750,755
Commitments and Contingencies
Stockholders' (deficiency) equity:
Preferred stock, $0.0001 par value: 50,000,000 shares authorized; none issued and outstanding		-			-
Common stock, $0.0001 par value: 250,000,000 shares authorized; 81,001,796 and 72,000,000 shares issued and outstanding, respectively		8,100			7,200
Common stock, $0.0001 par value: 250,000,000 shares authorized; 81,880,963 and 72,000,000 shares issued and outstanding, respectively		8,188			7,200
Additional paid in capital		4,~~434~~534,~~648~~061			3,707,680
Shares Issuable		-			1,056,159
Accumulated deficit		(5,~~045~~067,~~376~~077	)		(4,736,867	)
Total stockholders' (deficiency) equity		(~~602~~524,~~628~~828	)		34,172
Total liabilities and stockholders' (deficiency) equity	$	~~640~~427,~~206~~192		$	784,927

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

AV Therapeutics, Inc. and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For The Six Months Ended June 30, 2014			For The Six Months Ended June 30, 2013
	For The Nine Months Ended September 30, 2014			For The Nine Months Ended September 30, 2013
Revenues	$	-		$	-
Operating expenses:
Consulting fees		~~482~~638,~~137~~555			990,~~804~~936
Research and development fees		~~294~~469,~~325~~563			60257,~~300~~512
Patent legal fees		62,~~606~~605			63,573
General and administrative		~~121~~32,~~004~~802			2931,~~112~~808
Depreciation and amortization		1015,~~304~~456			1015,~~303~~455
Total operating expenses		~~970~~1,~~376~~218,981			~~173~~459,~~092~~284
Loss from operations		(~~970~~1,~~376~~218,981	)		(~~173~~459,~~092~~284	)
Other income (expense):
Interest expense		-			(~~524~~691	)
Unrealized gain on change in fair value of derivative liabilities		~~661~~888,~~867~~771			-
Total other income (expense)		~~661~~888,~~867~~771			(~~524~~691	)
Net loss	$	(~~308~~330,~~509~~210	)	$	(~~173~~459,~~616~~975	)
Net Loss Per Share - Basic and Diluted	$	(0.00	)	$	(0.0001	)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted		7879,~~629~~645,~~577~~135			6667,~~990~~195,~~381~~016

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

AV Therapeutics, Inc. and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For The Three Months Ended June 30, 2014			For The Three Months Ended June 30, 2013
	For The Three Months Ended September 30, 2014			For The Three Months Ended September 30, 2013
Revenues	$	-		$	-
Operating expenses:
Consulting fees		~~314~~81,~~387~~566			381,~~554~~132
Research and development fees		~~179~~155,~~075~~346			33197,~~300~~212
Patent legal fees		~~1,788~~-			~~11,270~~-
General and administrative		696,~~097~~541			182,~~338~~696
Depreciation and amortization		5,152			5,~~151~~152
Total operating expenses		~~569~~248,~~499~~605			71286,~~613~~192
Loss from operations		(~~569~~248,~~499~~605	)		(71286,~~613~~192	)
Other income (expense):
Interest expense		-			(~~200~~167	)
Unrealized gain on change in fair value of derivative liabilities		~~661~~226,~~867~~904			-
Total other income (expense)		~~661~~226,~~867~~904			(~~200~~167	)
Net Income (loss)	$	92,368		$	(71,813	)
Net loss	$	(21,701	)	$	(286,359	)
Earnings (Loss) Per Share - Basic and Diluted	$	0.00		$	(0.00	)
Net Loss Per Share - Basic and Diluted	$	0.00		$	0.00
Weighted Average Number of Common Shares Outstanding - Basic and Diluted		8081,~~258~~747,~~214~~177			67,~~346~~503,~~421~~930

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

AV Therapeutics, Inc. and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For The Six Months Ended			For The Six Months Ended
	For The Nine Months Ended			For The Nine Months Ended
	June 30, 2014			June 30, 2013
	September 30, 2014			September 30, 2013
Cash flows from operating activities:
Net loss	$	(~~308~~330,~~509~~210	)	$	(~~173~~459,~~616~~975	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization		1015,~~088~~132			1015,~~087~~131
Depreciation		~~216~~324			~~216~~324
Stock-based compensation		~~227~~281,~~602~~603			-
Unrealized gain on change in fair value of derivative liabilities		(~~661~~888,~~867~~771	)		-
Changes in operating assets and liabilities:
Prepaid expenses		2939,250			-
Accounts payable and accrued expenses		7758,~~053~~643			~~(17~~197,~~134~~145	)
Net cash used in operating activities		(~~626~~824,~~167~~029	)		(~~180~~247,~~447~~375	)
Cash flows from financing activities:
Proceeds received from issuance of common stock and warrants, net of issuance costs		525,000			175,000
Proceeds received from issuance of common stock, net of issuance costs		525,000			225,000
Repayments of note payable - related parties		(4,000	)		-
Proceeds received from note payable - related parties		(4,000	)		-
Net cash provided by financing activities		521,000			~~175~~225,000
Net decrease in cash		(105,167	)		(5,447	)
Net (decrease) increase in cash		(303,029	)		(22,375	)
Cash at beginning of period		576,251			97,436
Cash at end of period	$	~~471~~273,~~084~~222		$	9175,~~989~~061
Supplemental disclosures:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-
Non-cash investing and financing activities:
Recognition of derivative liability - warrants	$	1,080,893		$	-
Issuance of common stock in settlement of previously accrued executive compensation	$	72,000		$	-
Issuance of common stock in settlement of previously accrued consulting fees	$	27,500		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

AV Therapeutics, Inc. and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS

Organization – AV Therapeutics, Inc. (the “Company”) is a Delaware corporation formed on November 14, 2011 under the name “Aquino Milling Inc.” Under its initial business plan, the Company intended to purchase rice milling equipment and commence rice milling operations. On June 10, 2013, the Company changed its name to “Code 2 Action, Inc.” On July 30, 2013, the Company changed its name to “Merica Corp.” The Company was unable to implement its business plan and prior to the Reverse Acquisition (discussed below), Merica did not have any active business.

On December 13, 2013 (the “Closing Date”), the Company along with AVT Acquisitions, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (the “Subsidiary”) entered into and closed an Agreement and Plan of Merger (the “Merger Agreement”) with Advanced Vaccine Therapeutics, Inc., a Delaware corporation (formerly known as AV Therapeutics, Inc.) (“AVT”). Pursuant to the Merger Agreement, (i) the Subsidiary merged into AVT, such that AVT became a wholly-owned subsidiary of the Company, and (ii) the Company issued 58,000,000 shares, of the Company’s common stock to the shareholders of AVT, in exchange for the cancellation of all of the issued and outstanding shares of common stock of AVT.

Effective on the Closing Date, pursuant to the Merger Agreement, AVT became a wholly owned subsidiary of the Company. The acquisition of AVT is treated as a reverse acquisition (the “Reverse Acquisition”), and the business of AVT became the business of the Company. At the time of the Reverse Acquisition, Merica was not engaged in any significant active business.

In connection with the Merger Agreement~~, in addition to the foregoing~~:

(i) Effective on the Closing Date, 70,000,000 shares of common stock were returned to the Company for cancellation (the “Share Cancellation”).

(ii) AVT assumed notes payable with an aggregate value of $7,320. Shortly after the Reverse Acquisition in 2013, the holders of the notes converted the notes payable into shares of the Company’s common stock at $0.20 per share. The Company included the $7,320 in shares issuable on the consolidated balance sheet at December 31, 2013 as the 36,596 shares of common stock were issued on January 8, 2014 due to administrative delays.

Nature of Operations - The Company is an early stage biopharmaceutical company whose planned principal operations are to discover, develop and commercialize therapeutics to advance the care of patients suffering from cancer. The Company’s activities are supported by its patents, patent applications, provisional patent applications, and other proprietary intellectual property surrounding capridine and immunogens for treatment of infectious diseases and specifically, prostate cancer, amongst others. To date, the Company has not developed any commercial products. The Company’s activities are subject to significant risks and uncertainties, which are disclosed in Note 2.

References to “Merica” refer to the Company and its business prior to the Reverse Acquisition.

NOTE 2. GOING CONCERN AND MANAGEMENT’S PLANS

As of ~~June~~September 30, 2014, the Company had a working capital deficiency and stockholders’ deficiency of $~~741~~658,~~000~~048 and $~~602~~524,~~628~~828, respectively. The Company did not generate any revenues and incurred ~~net~~ losses from operations of $~~308~~1,~~509~~218,981 during the ~~six~~nine months ended ~~June~~September 30, 2014. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company's main sources of operating funds since inception have been contributions from its founders and debt and equity financings. The Company intends to raise additional capital through private debt and equity investors. There is no assurance that it will be successful in raising any additional funds or that any future funds it raises will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation – The condensed consolidated financial statements include the accounts of AV Therapeutics, Inc. and its wholly-owned subsidiary, Advanced Vaccine Therapeutics, Inc. Intercompany balances and transactions have been eliminated upon consolidation.

Table of Contents

AV Therapeutics, Inc. and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Basis of Presentation – The accompanying unaudited condensed consolidated financial statements as of ~~June~~September 30, 2014 and for the ~~six~~nine and three months then ended have been prepared in accordance with ~~the~~ GAAP for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The unaudited condensed consolidated balance sheet as of ~~June~~September 30, 2014 and the condensed consolidated statements of operations for the ~~six~~nine and three months ended ~~June~~September 30, 2014, and the condensed consolidated statements of cash flows for the ~~six~~nine months ended ~~June~~September 30, 2014 and 2013 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the ~~six~~nine and three months ended ~~June~~September 30, 2014 are not necessarily indicative of results to be expected for the year ending December 31, 2014 or for any future interim period. The condensed consolidated balance sheet at December 31, 2013 has been derived from audited consolidated financial statements. However, it does not include all of the information and notes required by GAAP for complete consolidated financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2013, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on March 31, 2014.

Use of Estimates—The Company prepares the financial statements in accordance with GAAP which accordingly, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s common stock, stock-based compensation, the fair value of warrant liabilities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.

Research and Development - Research and development expenses consist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates, compensation and other expenses for research and development, including personnel, supplies and development materials, costs for consultants and related contract research and facility costs. Expenditures relating to research and development are expensed as incurred.

Intangible Assets - Intangible assets are comprised of patents and licenses with original estimated useful lives of 10-15 years. Once placed into service, the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis. As of ~~June~~September 30, 2014 the Company has exclusive rights to four patents in the United States, pursuant to license agreements with the patent owners, including two immunological patents related to vaccine development and delivery mechanism, and one additional pending patent in the United States. Costs incurred by the Company in connection with developing patents internally are expensed as incurred. Amortization expense amounted to $1015,~~088~~456 and $1015,~~087~~455 for the ~~six~~nine months ended ~~June~~September 30, 2014 and 2013, respectively.

Impairment of Long-Lived Assets - The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. The Company has not identified any such impairment losses at ~~June~~September 30, 2014.

Revenue Recognition - Revenue from license fees and grants is recognized when the following criteria are met: persuasive evidence of an arrangement exists, services have been rendered, the contract price is fixed or determinable, and collection is reasonably assured. In licensing arrangements, delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. For the ~~six~~nine and three months ended ~~June~~September 30, 2014 and 2013, the Company did not recognize any revenue.

For revenue contracts that contain multiple elements, revenue arrangements with multiple deliverables are divided into separate units of accounting if the delivered item has value to the customer on a standalone basis and there is objective and reliable evidence of the fair value of the undelivered item.

Earnings (Loss) per Share - Basic earnings and loss per share are computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings and loss per share are computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of 3,362,500 warrants (using the if-converted method). Diluted earnings and loss per share excludes the shares issuable upon the exercise of 3,362,500 warrants from the calculation of earnings (loss) per share as their effect would be antidilutive for the three and six months ended June 30, 2014.

Table of Contents

AV Therapeutics, Inc. and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Loss per Share - Basic loss per share is computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Diluted earnings and loss per share excludes the shares issuable upon the exercise of 3,362,500 warrants from the calculation of earnings (loss) per share as their effect would be antidilutive for the three and nine months ended September 30, 2014. No potentially dilutive securities were outstanding as of ~~June~~September 30, 2013.

Fair Value of Financial Instruments - The financial instruments consist of cash, accounts payables, accrued expenses, and short-term credit obligations. The carrying amounts of the financial instruments approximate their respective current fair values due to their relatively short maturities. The carrying amounts of short term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, are comparable to rates of returns for instruments of similar credit risk.

Pursuant to the requirements of ASC 820, the Company’s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:

Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges.

Level 2: Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3: Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.

Stock-Based Compensation - The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company incurred stock-based compensation expense for the ~~six~~nine and three months ended ~~June~~September 30, 2014 of $~~227~~281,~~602~~603 and $~~197~~54,~~602~~001, respectively. No stock-based compensation expense was incurred during the ~~six~~nine and three months ended ~~June~~September 30, 2013.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, "Income Taxes." Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity's financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. Generally, the tax authorities may examine the partnership/corporate tax returns for three years from the date of filing. The Company has identified its federal return and its state tax return in New York as “major” tax jurisdictions, as defined.

~~Recent~~Reclassification ~~Accounting~~– Pronouncements - In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain ~~Financial~~accounts ~~Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance~~ in ~~Topic 810, Consolidation." This ASU removes~~ the ~~definition~~prior ofperiod’s acondensed ~~development~~consolidated ~~stage entity from the ASC, thereby removing the~~ financial ~~reporting~~statements ~~distinction~~have ~~between~~been ~~development~~reclassified ~~stage entities and other reporting entities from GAAP. In addition, the ASU eliminates the requirements~~ for ~~development~~comparative ~~stage~~purposes ~~entities~~ to ~~(1)~~conform ~~present~~with ~~inception-to-date~~the ~~information~~presentation in the ~~statements~~current ~~of operations, cash flows, and stockholders~~period’s ~~equity,~~condensed ~~(2)~~consolidated ~~label the~~ financial statements. asThese ~~those~~reclassifications ofhave ~~a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is~~ no ~~longer~~effect a development stage entity that in prior years it had been in the development stage. This ASU is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The Company has elected to adopt this ASU effective with this Quarterly Report on ~~Form 10-Q and its adoption resulted in the removal of~~ previously ~~required~~recorded ~~development stage disclosures~~losses.

Table of Contents

AV Therapeutics, Inc. and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

~~The~~Recent ~~FASB~~Accounting ~~has~~Pronouncements - In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-1210, ~~Compensation~~“Development –Stage ~~Stock~~Entities ~~Compensation~~ (Topic ~~718~~915): ~~Accounting~~Elimination ~~for~~of ~~Share-Based~~Certain ~~Payments~~Financial ~~When~~Reporting ~~the~~Requirements, ~~Terms~~Including of an ~~Award~~Amendment ~~Provide~~to ~~That~~Variable aInterest ~~Performance~~Entities ~~Target~~Guidance ~~Could~~in BeTopic ~~Achieved~~810, ~~after the Requisite Service Period~~Consolidation." This ASU ~~requires~~removes ~~that~~the definition of a ~~performance~~development ~~target~~stage ~~that~~entity ~~affects~~from ~~vesting~~the ASC, ~~and~~thereby ~~that~~removing ~~could~~the befinancial ~~achieved~~reporting ~~after~~distinction ~~the~~between ~~requisite~~development ~~service~~stage ~~period,~~entities beand ~~treated~~other asreporting aentities ~~performance~~from ~~condition~~GAAP. AsIn ~~such~~addition, the ~~performance~~ASU ~~target~~eliminates ~~should~~the ~~not~~requirements befor ~~reflected~~development instage ~~estimating~~entities ~~the~~to ~~grant~~(1) present inception-to-date ~~fair~~information ~~value~~in the statements of ~~the~~operations, ~~award.~~cash ~~This~~flows, ~~update~~and ~~further~~stockholders’ ~~clarifies~~equity, ~~that~~(2) ~~compensation~~label ~~cost~~the ~~should~~financial bestatements ~~recognized~~as inthose ~~the~~of ~~period~~a indevelopment ~~which~~stage itentity, ~~becomes~~(3) ~~probable~~disclose ~~that~~a description of the ~~performance~~development ~~target~~stage ~~will~~activities bein ~~achieved~~which ~~and~~the ~~should~~entity ~~represent~~is ~~the~~engaged, ~~compensation~~and ~~cost~~(4) ~~attributable~~disclose toin the ~~period(s)~~first ~~for~~year in which the ~~requisite~~entity ~~service~~is ~~has~~no ~~already~~longer ~~been~~a ~~rendered.~~development ~~The~~stage ~~amendments~~entity that in ~~this~~prior ~~ASU~~years ~~are~~it ~~effective~~had ~~for~~been ~~annual~~in ~~periods~~the ~~and~~development ~~interim~~stage. ~~periods~~This ~~within~~ASU ~~those~~is effective for annual reporting periods beginning after December 15, ~~2015~~2014, and interim periods therein. ~~Earlier~~Early adoption is permitted. The ~~adoption~~Company ofelected to adopt this ~~standard~~ASU isduring ~~not~~the ~~expected~~second toquarter ~~have~~of a2014 ~~material~~and ~~impact~~its onadoption ~~the~~resulted ~~Company’s~~in ~~condensed~~the ~~consolidated~~removal ~~financial~~of ~~position~~previously ~~and~~required ~~results~~development ofstage ~~operations~~disclosures.

The FASB has issued ASU No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The Company has elected to adopt this ASU effective with this quarterly report on Form 10-Q. The adoption of this standard is not expected to have a material effect of the Company’s financial position or results from operations.

The FASB has issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The guidance, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company has elected to early adopt the provisions of ASU 2014-15 in connection with the issuance of these unaudited condensed consolidated financial statements. Management’s evaluations of events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 2.

Subsequent Events- The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. See Note 9.

NOTE 4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

	June 30, 2014		December 31, 2013
	September 30, 2014		December 31, 2013
	(Unaudited)
Payroll taxes	$	~~202~~212,~~510~~456	$	182,618
Research consulting fees - related parties		232,000		204,000
Research consulting fees		183,000		204,000
Rent - Related party		5,000		5,000
Legal and professional fees		8964,~~593~~737		60,432
Accounts payable and accrued expenses	$	~~529~~465,~~103~~193	$	452,050

NOTE 5. STOCKHOLDERS’ DEFICIENCY

December 2013 Private Placement

In connection with the Merger Agreement disclosed in Note 1, as of the Closing Date the Company entered into and closed subscription agreements with accredited investors (the “December 2013 Investors”), pursuant to which the Company received an aggregate $709,999 and agreed to issue the December 2013 Investors 3,550,000 shares of common stock (“December 2013 Private Placement”). The 3,550,000 shares were issued on January 8, 2014 due to administrative delays.

The Company’s original private placement memorandum dated September 30, 2013 permitted the Company to sell up to 12,500,000 shares of common stock at $0.20 per share. On January 31, 2014, the Company amended its original private placement memorandum dated September 30, 2013 to (a) increase the amount the Company offered to $3,500,000 from $2,500,000 and (b) to add a warrant to the offering to purchase one share of common stock (for each two shares of common stock sold) at an exercise price of $0.40 and exercisable for a period of five years. In April 2014, the Company issued 1,775,000 warrants to the investors under the December 2013 Private Placement, in accordance with such amended terms.

April 2014 Private Placement

In April 2014, the Company entered into and closed subscription agreements (the “Subscription Agreements”) with accredited investors (the “April 2014 Investors”), pursuant to which the Company sold an aggregate of 2,750,000 shares of common stock and five-year warrants to purchase an aggregate of 1,375,000 shares of common stock to the April 2014 Investors at an exercise price of $0.40 per share for an aggregate purchase price of $550,000 (the “April 2014 Private Placement”). The Company retained Palladium Capital Advisors, LLC as the placement agent for the April 2014 Private Placement (the “Placement Agent”). The Company paid the Placement Agent a fee of $20,000 and issued to the Placement Agent 100,000 shares of common stock and 50,000 warrants with the same terms as the warrants issued to the April 2014 Investors. The Company incurred an additional $5,000 in professional fees in connection with the April 2014 Private Placement.

Other Common Stock Issuances

During the six months ended June 30, 2013, the Company received aggregate gross proceeds of $175,000 in connection with the private placement of 1,166,667 shares of its common stock at $0.15 per share.

Table of Contents

AV Therapeutics, Inc. and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 5. STOCKHOLDERS’ DEFICIENCY (CONTINUED)

April 2014 Private Placement

Other Common Stock Issuances

During the nine months ended September 30, 2013, the Company received aggregate gross proceeds of $225,000 in connection with the private placement of 1,166,667 shares of its common stock at $0.15 per share.

Warrants

The following table summarizes the Company’s warrants outstanding at ~~June~~September 30, 2014:

			Weighted		Weighted
			Average		~~Average~~Remaining		Average
	Number of		Exercise		~~Remaining~~ Life		Intrinsic
	Warrants		Price		In Years		Value
Outstanding at January 1, 2014		-	$	-		-		-
Issued		3,362,500		0.40		4.75		-
Issued in connection with offering		3,362,500		0.40		4.50		-
Exercised		-		-		-		-
Cancelled		-		-		-		-
Outstanding at June 30, 2014		3,362,500	$	0.40		4.75	$	-
Outstanding at September 30, 2014		3,362,500	$	0.40		4.50	$	-
Exercisable at June 30, 2014		3,362,500	$	0.40		4.75	$	-
Exercisable at September 30, 2014		3,362,500	$	0.40		4.50	$	-

NOTE 6. DERIVATIVE LIABILITIES

Fair value of financial instruments is defined as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Financial assets and liabilities with readily available, actively quoted prices or for which fair value can be measured from actively quoted prices in active markets generally have more pricing observability and require less judgment in measuring fair value. Conversely, financial assets and liabilities that are rarely traded or not quoted have less price observability and are generally measured at fair value using valuation models that require more judgment. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency of the asset, liability or market and the nature of the asset or liability. The Company has categorized its financial assets and liabilities measured at fair value into a three-level hierarchy.

During the six months ended June 30, 2014, the Company issued 3,362,500 warrants to purchase common stock, all of which contain net-cash settlement features giving the warrant holder the right to net-cash settlement in the event certain transactions occur. Therefore, the Company accounted for the warrants as derivative liabilities and valued them using the Black-Scholes option valuation model and the following weighted average assumptions on the following dates:11

	June 30, 2014			April 15, 2014			April 3, 2014
Warrant Liability:
Risk-free interest rate		0.30	%		0.30	%		0.30	%
Expected volatility		114	%		114	%		114	%
Expected life (in years)		4.75			5			5
Expected dividend yield		–			–			–
Number of shares		3,362,500			300,000			3,062,500
Fair value	$	419,026		$	74,475		$	1,006,418

Table of Contents

AV Therapeutics, Inc. and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 6. DERIVATIVE LIABILITIES (CONTINUED)

During the nine months ended September 30, 2014, the Company issued 3,362,500 warrants to purchase common stock, all of which contain net-cash settlement features giving the warrant holder the right to net-cash settlement in the event certain transactions occur. Therefore, the Company accounted for the warrants as derivative liabilities and valued them using the Black-Scholes option valuation model and the following weighted average assumptions on the following dates:

	September 30, 2014			April 15, 2014			April 3, 2014
Warrant Liability:
Risk-free interest rate		0.40	%		0.30	%		0.30	%
Expected volatility		138.5	%		114	%		114	%
Expected life (in years)		4.5			5			5
Expected dividend yield		–			–			–
Number of shares		3,362,500			300,000			3,062,500
Fair value	$	192,122		$	74,475		$	1,006,418

The risk-free interest rate was based on rates established by the Federal Reserve. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The expected life of the warrants was determined by their expiration dates. The expected dividend yield was based upon the fact that the Company has not historically paid dividends on its common stock, and does not expect to pay dividends on its common stock in the future.

Fair Value Measurement

Valuation Hierarchy

ASC 820, “Fair Value Measurements and Disclosures,” establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

11The following table provides the liabilities carried at fair value measured on a recurring basis as of September 30, 2014:

Fair Value Measurements at September 30, 2014

Quoted

Significant

Total

prices in

other

Significant

Carrying

active

observable

unobservable

Value at

markets

inputs

September 30, 2014

(Level 1)

(Level 2)

(Level 3)

Derivative liabilities

192,122

–

192,122

The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivative liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting department, who reports to the Principal Financial Officer, determines its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting department and are approved by the Principal Financial Officer.

Table of Contents

AV Therapeutics, Inc. and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 6. DERIVATIVE LIABILITIES (CONTINUED)

The following table provides the liabilities carried at fair value measured on a recurring basis as of June 30, 2014:

Fair Value Measurements at June 30, 2014

Quoted

Significant

Total

prices in

other

Significant

Carrying

active

observable

unobservable

Value at

markets

inputs

June 30, 2014

(Level 1)

(Level 2)

(Level 3)

Derivative liabilities

419,026

–

419,026

The carrying amounts of cash, prepaid expenses, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The carrying value of these instruments approximate fair value, as they bear terms and conditions comparable to market, for obligations with similar terms and maturities. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

Level 3 Valuation Techniques

Level 3 financial liabilities as of ~~June~~September 30, 2014 consist of the 3,362,500 warrants the Company issued during the ~~six~~nine months ended ~~June~~September 30, 2014, for which there is no current market ~~for these securities~~ such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. A significant decrease in the volatility or a significant decrease in the Company’s stock price, in isolation, would result in a significantly lower fair value measurement.

As of ~~June~~September 30, 2014, there were no transfers in or out of Level 3 from other levels in the fair value hierarchy.

The following table sets forth a summary of the changes in the fair value of our Level 3 financial liabilities that are measured at fair value on a recurring basis:

	For the six months ended			For the three months ended
	For the nine months ended			For the three months ended
	June 30, 2014			June 30, 2014
	September 30, 2014			September 30, 2014
Beginning balance	$	-		$	~~656~~419,~~518~~026
Recognition of derivative liabilities - warrants		1,080,893			424,375
Recognition of derivative liability - warrants		1,080,893			-
Unrealized gain on change in fair value of derivative liabilities		(661,867	)		(661,867	)
Net unrealized gain on derivative liabilities		(888,771	)		(226,904	)
Ending balance	$	~~419~~192,~~026~~122		$	~~419~~192,~~026~~122

NOTE 7. RELATED PARTY TRANSACTIONS

Lease Commitments

The Company rents office space from SB Lauren PC, an entity owned by the wife of the Company’s President, on a month to month basis for $1,200 per month. The arrangement commenced in 2012. Rent expense for each of the ~~six~~nine and three months ended ~~June~~September 30, 2014 and 2013 in connection with this arrangement was $710,~~200~~800 and $3,600, respectively. As of ~~June~~September 30, 2014 and December 31, 2013 $5,000 was included in accounts payable on the condensed consolidated balance sheet relating to this arrangement.

Consulting Agreements

On October 14, 2013, the Company entered into a consulting agreement with Dr. Abraham Mittelman to be the Company’s Chief Executive Officer for a term of 4 years. The agreement was effective on July 1, 2013. The Company agreed to pay Dr. Mittelman $72,000 per annum in common stock in equal increments, not less frequently than monthly, with a five (5) percent annual increase, plus normal out of pocket expenses. For the ~~six~~nine and three months ended ~~June~~September 30, 2014, the Company has recorded $3654,000 and $18,000, respectively in connection with this consulting agreement as research and development fees on the condensed consolidated statements of operations. For the nine and three months ended September 30, 2013, the Company recorded $18,000 in connection with this consulting agreement as research and development fees on the condensed consolidated statements of operations. On July 14, 2014, the Company issued Dr. Mittelman 650,000 shares of common stock having a fair value of $72,000 on the date of issuance in full satisfaction of previously accrued compensation of $72,000. The unpaid balance in the amount of $18,000, representing the fees owed for the third quarter of 2014, is included in accrued expenses as of September 30, 2014 on the condensed consolidated balance sheet. As of December 31, 2013, $36,000 was included in accrued expenses on the condensed consolidated balance sheet.

12On October 14, 2013, the Company entered into a consulting agreement with Dr. Raj Tiwari, to be the Company’s Chief Scientific Officer for a term of 4 years. The agreement was effective on July 1, 2013. The Company agreed to pay Dr. Tiwari $72,000 per annum in equal increments, not less frequently than monthly, with a five (5) percent annual increase, plus normal out of pocket expenses. In addition, the Company agreed to pay a signing bonus of $20,000 over two years in equal increments, not less frequently than monthly. For the nine and three months ended September 30, 2014, the Company has recorded $54,000 and $18,000, respectively in connection with this consulting agreement as research and development fees on the condensed consolidated statements of operations. For the nine and three months ended September 30, 2013, the Company recorded $38,000 in connection with this consulting agreement as research and development fees on the condensed consolidated statements of operations. The unpaid balance in the amount of $20,000 is included in accounts payable and accrued expenses as of September 30, 2014 on the condensed consolidated balance sheet. As of December 31, 2013, $20,000 was included in accounts payable and accrued expenses on the consolidated balance sheet.

Table of Contents

AV Therapeutics, Inc. and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 7. RELATED PARTY TRANSACTIONS (CONTINUED)

On October 14, 2013, the Company entered into a consulting agreement with Dr. Jan Geliebter to be the Company’s Secretary for a term of 4 years. The agreement was effective on July 1, 2013. The Company agreed to pay Dr. Geliebter $1848,000 per annum in equal increments not less frequently than monthly, ~~respectively~~with a five (5) percent annual increase, plus normal out of pocket expenses. In addition, the Company agreed to pay a signing bonus of $35,000 over two years in equal increments, not less frequently than monthly. For the nine and three months ended September 30, 2014, the Company has recorded $36,000 and $12,000 in connection with this consulting agreement as research and development fees on the condensed consolidated statements of operations. For the nine and three months ended September 30, 2013, the Company recorded $47,000 in connection with this consulting agreement as research and development fees on the condensed consolidated statements of operations. The unpaid balance in the amount of $7259,000 is included in accrued expenses as of ~~June~~September 30, 2014 on the condensed consolidated balance sheet. As of December 31, 2013, $3659,000 was included in accrued expenses on the consolidated balance sheet.

On October 14, 2013, the Company entered into a consulting agreement with Dr. ~~Raj~~Robert ~~Tiwari,~~Suriano to be the Company’s ~~Chief~~Lab ~~Scientific~~Manager ~~Officer~~ for a term of 42 years. The agreement was effective on July 1, 2013. The Company agreed to pay Dr. ~~Tiwari~~Suriano $7224,000 per annum in equal increments, not less frequently than monthly, with a five (5) percent annual increase, plus normal out of pocket expenses. In addition, the Company agreed to pay a signing bonus of $2010,000 over two years in equal increments, not less frequently than monthly. Payments pursuant to the consulting agreement accrue as of the date of the consulting agreement and will commence once the Company has raised $2.5 million through a financing. For the ~~six~~nine and three months ended ~~June~~September 30, 2014, the Company has recorded $3618,000 and $186,000 in connection with this consulting agreement as research and development fees on the condensed consolidated statement of operations. For the nine and three months ended September 30, ~~respectively~~2013, the Company recorded $26,000 in connection with this consulting agreement as research and development fees on the condensed consolidated statements of operations. The unpaid balance in the amount of $2022,000 is included in ~~accounts payable and~~ accrued expenses as of ~~June~~September 30, 2014 on the condensed consolidated balance sheet. As of December 31, 2013, $20,000 was included in ~~accounts payable and~~ accrued expenses on the consolidated balance sheet.

On October 14, 2013, the Company entered into a consulting agreement with Dr. ~~Jan~~Debabrata ~~Geliebter~~Banerjee to be a research consultant for the Company’s ~~Secretary~~ for a term of 4 years. The agreement was effective on July 1, 2013. The Company agreed to pay ~~Dr.~~Banerjee ~~Geliebter~~ $48,000 per annum in equal increments, not less frequently than monthly, with a five (5) percent annual increase, plus normal out of pocket expenses. In addition, the Company agreed to pay a signing bonus of $35,000 over two years in equal increments, not less frequently than monthly. Payments pursuant to the consulting agreement accrue as of the date of the consulting agreement and will commence once the Company has raised $2.5 million through a financing. For the ~~six~~nine and three months ended ~~June~~September 30, 2014, the Company has recorded $2436,000 and $12,000 in connection with this consulting agreement as research and development fees on the condensed consolidated statements of operations. For the nine and three months ended September 30, 2013, the Company recorded $71,000 in connection with this consulting agreement as research and development fees on the condensed consolidated statements of operations. The unpaid balance in the amount of $59,000 is included in accrued expenses as of ~~June~~September 30, 2014 on the condensed consolidated balance sheet. As of December 31, 2013, $59,000 was included in accrued expenses on the consolidated balance sheet.

On October 14, 2013, the Company entered into a consulting agreement with Dr. Robert Suriano to be the Company’s Lab Manager for a term of 2 years. The agreement was effective on July 1, 2013. The Company agreed to pay Dr. Suriano $24,000 per annum in equal increments, not less frequently than monthly, with a five (5) percent annual increase, plus normal out of pocket expenses. In addition, the Company agreed to pay a signing bonus of $10,000 over two years in equal increments, not less frequently than monthly. Payments pursuant to the consulting agreement shall accrue as of the date of the consulting agreement and commence once the Company has raised $2.5 million through a financing. For the six and three months ended June 30, 2014, the Company has recorded $12,000 and $6,000 in connection with this consulting agreement as research and development fees on the condensed consolidated statement of operations. The unpaid balance in the amount of $22,000 is included in accrued expenses as of June 30, 2014 on the condensed consolidated balance sheet. As of December 31, 2013, $20,000 was included in accrued expenses on the consolidated balance sheet.

On October 14, 2013, the Company entered into a consulting agreement with Dr. Debabrata Banerjee to be a research consultant for the Company for a term of 4 years. The agreement was effective on July 1, 2013. The Company agreed to pay Banerjee $48,000 per annum in equal increments, not less frequently than monthly, with a five (5) percent annual increase, plus normal out of pocket expenses. In addition, the Company agreed to pay a signing bonus of $35,000 over two years in equal increments, not less frequently than monthly. Payments pursuant to the consulting agreement shall accrue as of the date of the consulting agreement and commence once the Company has raised $2.5 million through a financing. For the six and three months ended June 30, 2014, the Company has recorded $24,000 and $12,000 in connection with this consulting agreement as research and development fees on the condensed consolidated statements of operations. The unpaid balance in the amount of $59,000 is included in accrued expenses as of June 30, 2014 on the condensed consolidated balance sheet. As of December 31, 2013, $59,000 was included in accrued expenses on the consolidated balance sheet.

Payroll Taxes

From the Company’s inception in 2007 through ~~June~~September 30, 2014, the Company considered certain executives to be consultants of the Company rather than employees. If the executives were treated as employees during ~~the~~this ~~above~~ period, the Company would have been required to withhold and remit payroll taxes to the respective taxing authorities. ~~This~~The ~~position~~Company’s treatment of these executives as consultants may be subject to audit by the Internal Revenue Service and other state and local taxing authorities, which, upon review, could result in an unfavorable outcome if it is determined that such individuals’ compensation should have been reported on the basis of antheir ~~employee~~being employees rather than ~~a consultant~~consultants. The Company has recorded charges of approximately $1929,~~892~~838 and $9,946 for the ~~six~~nine and three months ended ~~June~~September 30, 2014, respectively. The Company has recorded charges of approximately $1731,~~442~~212 and $13,770 for the ~~six~~nine and three months ended ~~June~~September 30, 2013, respectively in consulting and research and development fees on the condensed consolidated statements of operations for additional compensation (including penalties and interest) on behalf of the executives, should the Company be challenged by the taxing authorities and it is determined ~~their~~that ~~position~~the Company’s treatment of these executives as consultants is without merit.

13Director Compensation

In December 2013, the Company reached an agreement with a former member of its Board of Directors, Mr. Douglas Cole, whereby the Company agreed to issue 200,000 shares of common stock to Mr. Cole for his past services as a director at similar terms in the December 2013 Private Placement. Due to administrative delays, the shares were issued on January 8, 2014.

Table of Contents

AV Therapeutics, Inc. and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 7. RELATED PARTY TRANSACTIONS (CONTINUED)

Director Compensation

In December 2013, the Company reached an agreement with a former member of its Board of Directors, Mr. Douglas Cole, whereby the Company agreed to issue 200,000 shares of common stock to Mr. Cole for his past services as a Director at similar terms in the December 2013 Private Placement. Due to administrative delays, the shares were issued on January 8, 2014.

Sichenzia Ross Friedman Ference LLP

On August 27, 2013 the Company engaged Sichenzia Ross Friedman Ference LLP (“SRFF”) as its legal representative for a going public transaction. The Company agreed to pay SRFF $50,000 and 325,000 shares of common stock for providing this service. Once the Company was able to complete such transaction, which it did in December 2013, the Company agreed to pay $4,500 per month for general legal matters, for which the Company will have the option to pay such fees in registered common stock valued at $6,000. The Company paid SRFF the $50,000 in cash during the year ended December 31, 2013 and included the value of the common stock to be issued of $65,000 in shares issuable on the consolidated balance sheet as of December 31, 2013. The shares were issued on January 8, 2014. For the ~~six~~nine and three months ended ~~June~~September 30, 2014, the Company has recorded $~~107~~121,~~242~~942 and $9314,~~742~~700, respectively in connection with this agreement, which is recorded as consulting fees on the condensed consolidated statement of operations. For the nine and three months ended September 30, 2013, the Company recorded $50,000 in connection with this agreement, which is recorded as consulting fees on the condensed consolidated statement of operations. There is noan unpaid amount of $10,200 included in accounts payable as of ~~June~~September 30, 2014 on the condensed consolidated balance sheet.

During the ~~six~~nine months ended ~~June~~September 30, 2014, the Company amended the terms of its original agreement, whereby it agreed to issue SRFF 162,500 warrants to purchase common stock containing the same terms as the warrants issued in the April 2014 Private Placement. The grant date fair value of the warrant issued to SRFF was $53,402 and has been included in professional fees on the condensed consolidated statements of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2014. On April 21, 2014, the Company issued Darrin Ocasio, a partner at SRFF, an additional 134,200 shares of ~~its~~ common stock with an aggregate grant date fair value of $26,840, or $0.20 per share, in connection with services rendered to the Company during the ~~six~~nine months ended ~~June~~September 30, 2014.

Objective Equity, LLC

On December 13, 2013, the Company entered into an agreement with Objective Equity, LLC (“Objective Equity”) to act on behalf of the Company as its non-exclusive placement agent and assist the Company in raising capital. In consideration for such services, the Company agreed to pay Objective Equity (a) a cash placement fee of 8% of the total purchase price of securities sold, including all amounts received by the Company upon exercise of any warrants issued in such raise and, (b) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise. The agreement terminates on December 13, 2014. Mr. Douglas Cole, a former ~~Director~~director of the Company is a partner in Objective Equity. On January 8, 2014, the Company amended the terms of its agreement with Objective Equity whereby both parties agreed that the Company would issue Objective Equity shares of common stock with a grant date fair value equal to 8% of the total proceeds received by the Company. The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered. Of the total proceeds received by the Company in the December 2013 Private Placement, Objective Equity assisted the Company in the raising of the initial $660,000 and as a result, the Company included $52,800 in shares issuable at December 31, 2013. On January 8, 2014, the Company issued to designees of Objective Equity 264,000 shares of common stock.

During the ~~six~~nine months ended ~~June~~September 30, 2014, the Company issued designees of Objective Equity an additional 202,400 shares of common stock for services rendered to the Company with a grant date fair value of $40,480, or $0.20 per share.

NOTE 8. COMMITMENTS AND CONTINGENCIES

Legal Matters

From time to time, the Company is subject to legal proceedings arising in the ordinary course of business. Such matters are subject to uncertainties and outcomes are not predictable with assurance. Management believes at this time, there are no ongoing matters that will have a material adverse effect on the Company's business, financial position, results of operations, or cash flows, except as disclosed below.

On May 29, 2013, Highland Global Creek Partners, Inc. (the “Plaintiffs”) brought an action against the Company in the Supreme Court of New York, County of New York, alleging a breach of a consulting contract. The Plaintiffs are seeking a judgment directing the Company to issue and deliver 80,000,000 shares of its common stock and 10,000,000 shares of its Series A Preferred Stock. ~~As of the date of this filing, the Company does not have any preferred shares authorized.~~ In addition, the Plaintiffs are also seeking an order enjoining the Company from taking any action requiring shareholder approval without notice to Plaintiffs and/or the Plaintiffs participation, as well as an order declaring that any action requiring stockholder approval taken by the Company without notice to and/or the participation of the Plaintiffs is null and void. The Company has filed counterclaims against the Plaintiffs and will contest this matter vigorously. The Company has not recorded a provision for a potential loss as it is unable to state that an outcome in this matter is unfavorable or estimate the amount or range of a potential loss.

1415

Table of Contents

AV Therapeutics, Inc. and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 8. COMMITMENTS AND CONTINGENCIES (CONTINUED)

this matter vigorously. The Company has not recorded a provision for a potential loss as it is unable to state that an outcome in this matter is unfavorable or estimate the amount or range of a potential loss.

TotalCFO, LLC

On September 17, 2013, the Company engaged TotalCFO, LLC to provide consulting services related to its financial reporting for a period of one year unless sooner terminated by either party upon (90) day’s written notice. The Company agreed to pay TotalCFO, LLC (a) $2,500 per month in cash, (b) a monthly amount of registered common shares having a grant date fair value of $2,500 (to be calculated at a 25% discount to market) and (c) all pre-approved expenses. The Company incurred professional fees expense to TotalCFO, LLC of $3045,000 and $15,000 for the ~~six~~nine and three months ended ~~June~~September 30, 2014. AsThe Company incurred professional fees expense to TotalCFO, LLC of ~~June~~$5,000 for the nine and three months ended September 30, 2013. On July 14, 2014, the Company issued TotalCFO, LLC 229,167 shares of common stock in satisfaction of its previously accrued outstanding balance of $2527,~~000~~500. ~~per~~As ~~detail~~ of September 30, 2014, $7,500 is included in accounts payable and accrued expenses on the condensed consolidated balance sheet in connection with this agreement.

On January 8, 2014, the Company issued Total CFO, LLC 100,000 shares of common stock at similar terms to the shares issued in the December 2013 Private Placement as a one-time bonus for consideration of their services in connection with the Company’s going-public transaction in December of 2013.

RedChip Companies, Inc.

On December 14, 2012 the Company entered into an agreement with RedChip Companies, Inc. (“RedChip”) to assist the Company with various ~~legal,~~ professional, investor relations and other services in connection with a going-public transaction involving the Company. In December of 2013, the Company and RedChip agreed to amend the terms of the agreement whereby the Company would issue RedChip 805,200 shares of common stock in full satisfaction for amounts owed in connection with services performed by RedChip at $0.20 per share. The shares were issued on January 8, 2014.

In addition, in December 2013, the Company entered into an investor relations agreement with RedChip for a term of four months commencing January 1, 2014. In connection with the investor relations agreement the Company agreed to (a) pay RedChip a $60,000 cash payment, which was made on December 13, 2013 and (b) issue RedChip 200,000 shares of common stock at $0.20 per share, which were issued on January 8, 2014. In April 2014, the Company agreed to issue RedChip an additional 334,400 shares of common stock in connection with services rendered to the Company, also at $0.20 per share. During the ~~six~~nine and three months ended ~~June~~September 30, 2014, the Company recorded consulting fees of $227,630 and $~~152,630~~0 in its condensed consolidated statement of operations, of which $106,880 was non-cash stock-based compensation expense. No expense was incurred in connection with this agreement in 2013.

John Carris Investments, LLC

On March 10, 2014, the Company entered into an agreement with John Carris Investments, LLC (“John Carris”) to act on behalf of the Company as its non-exclusive placement agent and assist the Company in raising up to a maximum of $3.5 million. In consideration for such services, the Company agreed to pay John Carris (a) a cash placement fee of 10% of the total purchase price of securities sold, including all amounts received by the Company upon exercise of any warrants issued in such raise, (b) a non-accountable expense allowance in the amount of 2% of the aggregate consideration received by the Company, and (c) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise. The Company paid John Carris a $15,000 non-refundable expense retainer. The agreement had a three month term and expired in accordance with its terms on June 10, 2014. During the ~~six~~nine ~~and three~~ months ended ~~June~~September 30, 2014, the company recorded consulting fees of $15,000 ~~and $0, respectively~~ in its condensed consolidated statement of operation in connection with this agreement. As of ~~June~~September 30, 2014, the Company is no longer party to any agreement with John Carris and owes John Carris no additional fees.

~~NOTE 9. SUBSEQUENT EVENTS~~16

On July 14, 2014, the Company issued TotalCFO, LLC 229,167 shares of common stock in satisfaction of its outstanding balance of $27,500.

On July 14, 2014, the Company issued Dr. Mittelman 650,000 shares of common stock in full satisfaction of accrued compensation of $72,000 in addition to his July 2014 compensation of $6,000.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations for the ~~six~~nine and three months ended ~~June~~September 30, 2014 should be read together with our condensed consolidated financial statements and related notes included elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements and information relating to our business that reflect our current views and assumptions with respect to future events and are subject to risks and uncertainties that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These forward-looking statements speak only as of the date of this report. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or achievements. Except as required by applicable law, including the securities laws of the United States, we expressly disclaim any obligation or undertaking to disseminate any update or revisions of any of the forward-looking statements to reflect any change in our expectations with regard thereto or to conform these statements to actual results.

OVERVIEW

AV Therapeutics, Inc. (the “Company”) is a Delaware corporation formed on November 14, 2011 under the name “Aquino Milling Inc.” Under its initial business plan, the Company intended to purchase rice milling equipment and commence rice milling operations. On June 10, 2013, the Company changed its name to “Code 2 Action, Inc.” On July 30, 2013, the Company changed its name to “Merica Corp.” The Company was unable to implement its business plan. Prior to the Reverse Acquisition (discussed below), Merica did not have any active business.

On December 13, 2013 (the “Closing Date”), the Company entered into and closed an Agreement and Plan of Merger (the “Merger Agreement”), with AVT Acquisitions, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (the “Subsidiary”) and Advanced Vaccine Therapeutics, Inc., a Delaware corporation (formerly known as AV Therapeutics, Inc.) (“AVT”). Pursuant to the Merger Agreement, (i) the Subsidiary merged into AVT, such that AVT became a wholly-owned subsidiary of the Company, and (ii) the Company issued 58,000,000 shares of the Company’s common stock to the shareholders of AVT, in exchange for the cancellation of all of the issued and outstanding shares of common stock of AVT.

AVT is a Delaware corporation formed on February 11, 2011. Prior to the date of incorporation, the activities of AVT were carried out through Applied Vaccine Technology, LLC (“AVT, LLC”), a Delaware limited liability company formed in July 2007 and an entity with common ownership as AVT. The operations and net assets of AVT, LLC were acquired by AVT on February 11, 2011 and AVT, LLC has since been an inactive entity.

References to “we”, “us”, “our” and similar words refer to the Company and its wholly-owned subsidiary, AVT, unless the context otherwise requires, and prior to the effectiveness of the Reverse Acquisition, these terms refer to AVT. References to “Merica” refer to the Company and its business prior to the Reverse Acquisition.

Our Business

The Company is primarily engaged in the business of developing cancer therapeutics and immunotherapeutic vaccines that can be used together with prevalent treatment modalities such as chemotherapy and radiation to treat active disease and to prevent metastases and recurrence. The Company has purchased the exclusive rights to a patented chemotherapeutic drug called “Capridine” that has been shown in preclinical models to have specific activity against prostate and colon cancer. This drug is expected to be the Company’s front line product specifically in prostate cancer where limited chemotherapy is available at the present time. Our immuno-therapeutics are based on the ability of certain proprietary reagents to re-educate or reprogram a failed immune system that can target previously unidentified micro-metastases. We intend to clinically develop both of these approaches independently specifically for prostate cancer. This drug was developed and patented by certain scientists on behalf of New York Medical College, including Dr. Raj Tiwari, our Chief Scientific Officer, who is also a professor at New York Medical College. The drug patents were thus issued to New York Medical College. AVT subsequently purchased an exclusive license to the drug, including the exclusive right to commercialize the drug. Under our agreement with New York Medical College, we agreed to pay New York Medical College 3% of net sales (as defined in the agreement) from commercialization of the drug patents, and 30% of sublicense fees. In addition to Dr. Raj Tiwari, Dr. Abraham Mittelman, our Chief Executive Officer, Dr. Jan Geliebter, our Corporate Secretary, and Dr. Debabrata Banerjee, our Clinical Development Officer, are also professors at New York Medical College.

1617

Table of Contents

We have, in the past, engaged New York Medical College to conduct research, pursuant to our supported research and license agreement with New York Medical College. In the future, we intend to expand our research efforts by identifying other promising research and funding that research through academic institutions (such as New York Medical College). Under such an arrangement, any patents would be granted to the academic institution and AVT in turn would enter into a licensing agreement with the academic institution for rights to the patent.

Our proprietary technology is easily adaptable to infectious diseases, which we believe enhances its market potential. We do not intend to market our own products, although we may decide to do so in the future. Instead, we intend to enter into agreements with large pharmaceutical companies whereby we will receive an upfront cash sum plus an ongoing royalty stream when the drug(s) or vaccine(s) are approved by the Food and Drug Administration (“FDA”) for use in the market. We will search for a partner(s) in early Phase II/III clinical trials of any particular treatment modality drug and or vaccine.

We believe, although we can provide no assurance, that with funding in the amount of approximately $10,000,000, we will be able to evaluate our first therapeutic pharmaceutical, the prostate cancer specific drug and a prostate cancer vaccine through Phase I clinical trials in humans within the next 12 to 18 months. We do not have any definitive agreements for funding and as such there cannot be any assurance that we will be successful in achieving our goals.

Results of Operations

Three and ~~six~~nine months ended ~~June~~September 30, 2014 compared with the three and ~~six~~nine months ended ~~June~~September 30, 2013

Revenue. ~~There~~We ~~were~~did nonot ~~revenues~~recognize ~~recognized~~any revenues during the three and ~~six~~nine months ended ~~June~~September 30, 2014 and 2013.

Operating Expenses. Operating expenses for the three months ended ~~June~~September 30, 2014, totaled ~~$569~~248,~~499~~605 and consisted of consulting fees of $~~314~~81,~~387~~566 paid for professional services, including legal, accounting and investor relations, research and development fees of $~~179~~155,~~075~~346 paid to consultants for providing scientific research as well as materials used in the lab, ~~patent legal fees of $1,788 for ongoing patent maintenance,~~ general and administrative costs of $696,~~096~~541, consisting of rent, travel and other miscellaneous expenses and depreciation and amortization of $5,152, consisting mainly of patent amortization.

For the three months ended ~~June~~September 30, 2013, operating expenses totaled $71286,~~613~~192 and consisted of consulting fees of $381,~~554~~132 paid for professional services, including legal and accounting, research and development fees of $33197,~~300~~212 paid to consultants for providing scientific research, ~~patent legal fees of $11,270 for ongoing patent maintenance,~~ general and administrative costs of $182,~~338~~696 consisting of rent, travel and other miscellaneous expenses and depreciation and amortization of $5,~~151~~152, consisting mainly of patent amortization.

Operating expenses for the ~~six~~nine months ended ~~June~~September 30, 2014, totaled $~~970~~1,~~376~~218,981 and consisted of consulting fees of $~~482~~638,~~137~~555 paid for professional services, including legal, accounting and investor relations, research and development fees of $~~294~~469,~~325~~563 paid to consultants for providing scientific research, patent legal fees of $62,~~606~~605 for ongoing patent maintenance, general and administrative costs of $~~121~~32,~~004~~802, consisting of rent, travel and other miscellaneous expenses and depreciation and amortization of $1015,~~303~~456, consisting mainly of patent amortization.

Operating expenses for the ~~six~~nine months ended ~~June~~September 30, 2013, totaled $~~173~~459,~~091~~284 and consisted of consulting fees of $990,~~804~~936 paid for professional services, including legal, accounting and investor relations, research and development fees of $60257,~~300~~512 paid to consultants for providing scientific research, patent legal fees of $63,573 for ongoing patent maintenance, general and administrative costs of $2931,~~112~~808, consisting of rent, travel and other miscellaneous expenses and depreciation and amortization of $1015,~~303~~455, consisting mainly of patent amortization.

The increase in expenditures for the three and ~~six~~nine months ended ~~June~~September 30, 2014 over the same period ended ~~June~~September 30, 2013 is due to the increased level of activity relating to the preparation of the pre investigational new drug application (“IND”) with the FDA for the Company’s Phase I testing and an increase in consulting and ~~professional~~research ~~fees~~and development relating to the Reverse Acquisition in the amount of $759,670. In addition, effective July 1, 2013, the Company entered into consulting agreements with Dr. Abraham Mittelman, Dr. Raj Tiwari, Dr. Jan Geliebter, Dr. Robert Suriano and Dr. Debabrata Banerjee to perform research and development services for the Company. As a result, consulting fees and research and development expenses included only three months of activity related to the consultants agreements for the period ended September 30, 2013 while the same expense categories include nine months of activity for the period ending September 30, 2014.

Net ~~Income (~~Loss). Net ~~income~~loss for the three months ended ~~June~~September 30, 2014, was $9221,~~368~~701, including a non-cash unrealized gain on the change in fair value of derivative liabilities of $~~661~~226,~~867~~904. The net loss for the three months ~~June~~September 30, 2013, was $~~(71~~286,~~813)~~359 including $~~200~~167 of interest expense on the amount owed under the licensing agreement. The net loss for the ~~six~~nine months ended ~~June~~September 30, 2014, was $~~(308~~330,~~509)~~210, including a non-cash unrealized gain on change in fair value of derivative liabilities of $~~661~~888,~~867~~771. The net loss for the ~~six~~nine months ended ~~June~~September 30, 2013 was $~~(173~~459,~~615)~~975 including $~~524~~691 of interest expense on the amount owed under the licensing agreement.

1718

Table of Contents

Liquidity and Capital Resources

Cash and Working Capital

We incurred alosses ~~net~~from ~~loss~~operations of $~~308~~1,~~509~~218,981 for the ~~six~~nine months ended ~~June~~September 30, 2014. As of ~~June~~September 30, 2014 the Company had cash and a stockholders’ deficiency of $~~471~~273,~~084~~222 and $~~602~~524,~~628~~828, respectively. At ~~June~~September 30, 2014, the Company had a working capital deficiency of $~~741~~658,~~000~~048. During the ~~six~~nine months ended ~~June~~September 30, 2014, the Company raised net proceeds of approximately $525,000 from the sale of common stock and warrants.

Cash Used in Operating Activities

Our primary ongoing uses of operating cash relate to payments to subcontractors and vendors for research and development, ongoing patent maintenance fees and professional fees. The timing of such payments is generally even throughout the year. Our vendors and subcontractors generally provide us with normal trade payment terms. During the ~~six~~nine months ended ~~June~~September 30, 2014, net cash used in operating activities amounted to $~~626~~824,~~167~~029 comprised of net loss of $~~308~~330,~~509~~210, negative adjustments to reconcile net loss to net cash used in operating activities of $~~423~~591,~~961~~712 and changes in operating assets and liabilities of $~~106~~97,~~303~~893 as compared to $~~180~~247,~~447~~375 for the ~~six~~nine months ended ~~June~~September 30, 2013, which comprised a net loss of $~~173~~459,~~615~~975, positive adjustments to reconcile net loss to net cash used in operating activities of $1015,~~303~~455 and changes in operating assets and liabilities of $17197,~~134~~145.

Cash Provided by Financing Activities

During the ~~six~~nine months ended ~~June~~September 30, 2014 and 2013, the Company received net proceeds of $525,000 and $~~175~~225,000, respectively, from common stock issuances. During the ~~six~~nine months ended ~~June~~September 30, 2014, The Company repaid $4,000 ~~was repaid~~ relating to a note payable owed to a related party

Sources of Liquidity

The Company incurred ~~net~~ losses from operations of $~~308~~1,~~509~~218,981 during the ~~six~~nine months ended ~~June~~September 30, 2014. As of ~~June~~September 30, 2014 the Company had a ~~negative~~ working capital deficiency and stockholders’ deficiency of $~~741~~658,~~000~~048 and $~~602~~524,~~628~~828, respectively. In April 2014, the Company raised aggregate gross proceeds of $550,000 from the private placement of common stock and warrants. In order to execute the Company's long-term strategic plan, the Company will need to raise additional funds, through public or private equity offerings, debt financings, or other means. The Company can give no assurance that additional funds will be available on reasonable terms, or available at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company’s ability to execute its business plan is dependent upon its ability to raise additional equity, secure debt financing, and/or generate revenue. Should the Company not be successful in obtaining the necessary financing, or generate sufficient revenue to fund its operations, the Company would need to curtail certain of its operational activities. The accompanying financial statements do not include any adjustments that might be necessary, should the Company be unable to continue as a going concern.

Off Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not have any undisclosed borrowings or debt, and we have not entered into any synthetic leases. We are, therefore, not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not required for a smaller reporting company.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out an evaluation by the Company’s Chief Executive Officer, who is also our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. As discussed below, management has concluded that as of ~~June~~September 30, 2014 our disclosure controls and procedures were not effective.

18As of December 31, 2013, we had identified certain matters that constituted a material weakness in our internal controls over financial reporting that continued to exist as of September 30, 2014. Specifically, we have difficulty in accounting for complex accounting transactions and have limited segregation of duties within our accounting and financial reporting functions. Segregation of duties within our Company is limited due to the small number of employees that are assigned to positions that involve the processing of financial information. Although we are aware that segregation of duties within our company is limited, we believe (based on our current roster of employees and certain control mechanisms we have in place), that the risks associated with having limited segregation of duties are currently insignificant. Additional time is required to expand our staff, fully document our systems, implement control procedures and test their operating effectiveness before we can definitively conclude that we have remediated our material weakness.

Table of Contents

As of December 31, 2013, we had identified certain matters that constituted a material weakness in our internal controls over financial reporting that continued to exist as of June 30, 2014. Specifically, we have difficulty in accounting for complex accounting transactions and have limited segregation of duties within our accounting and financial reporting functions. Segregation of duties within our Company is limited due to the small number of employees that are assigned to positions that involve the processing of financial information. Although we are aware that segregation of duties within our company is limited, we believe (based on our current roster of employees and certain control mechanisms we have in place), that the risks associated with having limited segregation of duties are currently insignificant. Additional time is required to expand our staff, fully document our systems, implement control procedures and test their operating effectiveness before we can definitively conclude that we have remediated our material weakness.

Limitations of the Effectiveness of Control

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations of any control system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal controls over financial reporting (as such term is defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended ~~June~~September 30, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

1920

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

There have no material developments to previously disclosed legal proceedings.

Item 1A. Risk Factors.

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In April 2014, the Company sold an aggregate of 2,750,000 shares of common stock and issued warrants to purchase an aggregate of 1,375,000 shares of common stock with an exercise price of $0.40 to accredited investors for total gross proceeds of $550,000. The Company paid Palladium Capital Advisors, LLC (“Palladium”) a fee of $20,000 and issued to Palladium 100,000 shares of common stock and warrants to purchase 50,000 shares of common stock at an exercise price of $0.40 for placement agent services in connection with the transaction.

On July 14, 2014, the Company issued an aggregate of 879,167 shares of common stock for services, including 650,000 shares to Abraham Mittelman , the Company’s chief executive officer, in accordance with Dr. Mittelman’s consulting agreement with the Company.

In connection with the foregoing, the Company relied on the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

No.		Description
31.1		Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive and Financial Officer
32.1		Section 1350 Certification of Chief Executive and Financial Officer
101.INS		XBRL Instance Document.
101.SCH		XBRL Taxonomy Schema.
101.CAL		XBRL Taxonomy Extension Calculation Linkbase.
101.DEF		XBRL Taxonomy Extension Definition Linkbase.
101.LAB		XBRL Taxonomy Extension Label Linkbase.
101.PRE		XBRL Taxonomy Extension Presentation Linkbase.

2021

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AV Therapeutics, Inc.
Date: August 19, 2014	By:	/s/ Abraham Mittelman
Date: November 17, 2014	By:	/s/ Abraham Mittelman
		Abraham Mittelman
		Chief Executive Officer and Chief Financial Officer (principal executive, financial and accounting officer)

2122

Filing Compare · AV Therapeutics, Inc.